Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study
Bright Minds Biosciences (NASDAQ: DRUG) has announced a virtual R&D Day scheduled for May 20, 2025, from 10:00 am to 11:30 am ET. The event will spotlight the company's focus on absence seizures and their ongoing BREAKTHROUGH study - a Phase 2 clinical trial evaluating BMB-101.
The webcast will feature presentations from Key Opinion Leaders (KOLs) in epilepsy research, examining the unmet needs in epilepsy patients. The BREAKTHROUGH study specifically evaluates the safety, tolerability, and efficacy of BMB-101 in adult patients with classic Absence Epilepsy and Developmental and Epileptic Encephalopathy (DEE).
The R&D Day will be accessible via webcast, with a replay available in the 'Investors' section under 'Events and Presentations' on the company's website.
Bright Minds Biosciences (NASDAQ: DRUG) ha annunciato una Giornata virtuale di Ricerca e Sviluppo prevista per il 20 maggio 2025, dalle 10:00 alle 11:30 ET. L'evento metterà in evidenza l'attenzione dell'azienda sulle crisi di assenza e il loro studio in corso BREAKTHROUGH - uno studio clinico di Fase 2 che valuta BMB-101.
La diretta web presenterà interventi di Key Opinion Leaders (KOLs) nella ricerca sull'epilessia, analizzando i bisogni non soddisfatti dei pazienti con epilessia. Lo studio BREAKTHROUGH valuta in particolare la sicurezza, la tollerabilità e l'efficacia di BMB-101 in pazienti adulti con epilessia da assenza classica e encefalopatia epilettica e dello sviluppo (DEE).
La Giornata di R&S sarà accessibile via webcast, con una replica disponibile nella sezione 'Investitori' sotto 'Eventi e Presentazioni' sul sito web dell'azienda.
Bright Minds Biosciences (NASDAQ: DRUG) ha anunciado un Día virtual de I+D programado para el 20 de mayo de 2025, de 10:00 a 11:30 am ET. El evento destacará el enfoque de la compañía en las crisis de ausencia y su estudio en curso BREAKTHROUGH, un ensayo clínico de Fase 2 que evalúa BMB-101.
La retransmisión contará con presentaciones de Key Opinion Leaders (KOLs) en investigación de epilepsia, analizando las necesidades no cubiertas en pacientes con epilepsia. El estudio BREAKTHROUGH evalúa específicamente la seguridad, tolerabilidad y eficacia de BMB-101 en pacientes adultos con epilepsia por ausencia clásica y encefalopatía epiléptica y del desarrollo (DEE).
El Día de I+D será accesible vía webcast, con una repetición disponible en la sección 'Inversores' bajo 'Eventos y Presentaciones' en la página web de la compañía.
Bright Minds Biosciences (NASDAQ: DRUG)는 2025년 5월 20일 오전 10시부터 11시 30분(동부시간)까지 가상 연구개발(R&D) 데이를 개최할 예정입니다. 이번 행사는 회사가 결신발작(absence seizures)에 집중하고 있으며, 현재 진행 중인 BREAKTHROUGH 연구 - BMB-101을 평가하는 2상 임상 시험에 대해 조명할 것입니다.
웹캐스트에서는 간질 연구 분야의 주요 의견 리더(Key Opinion Leaders, KOLs)들이 발표를 진행하며, 간질 환자들의 충족되지 않은 필요를 살펴봅니다. BREAKTHROUGH 연구는 고전적 결신 간질 및 발달성 간질뇌병증(Developmental and Epileptic Encephalopathy, DEE)을 가진 성인 환자에서 BMB-101의 안전성, 내약성 및 효능을 평가합니다.
R&D 데이는 웹캐스트로 진행되며, 회사 웹사이트의 '투자자' 섹션 내 '이벤트 및 프레젠테이션'에서 다시보기 서비스를 이용할 수 있습니다.
Bright Minds Biosciences (NASDAQ : DRUG) a annoncé une Journée virtuelle de R&D prévue le 20 mai 2025, de 10h00 à 11h30 ET. L'événement mettra en lumière l'intérêt de la société pour les crises d'absence et son étude en cours BREAKTHROUGH – un essai clinique de phase 2 évaluant le BMB-101.
La webdiffusion comprendra des présentations de Key Opinion Leaders (KOLs) en recherche sur l’épilepsie, examinant les besoins non satisfaits des patients épileptiques. L’étude BREAKTHROUGH évalue spécifiquement la sécurité, la tolérance et l’efficacité du BMB-101 chez des patients adultes atteints d’épilepsie d'absence classique et d'encéphalopathie épileptique et développementale (DEE).
La Journée R&D sera accessible via webcast, avec une rediffusion disponible dans la section « Investisseurs » sous « Événements et Présentations » sur le site internet de la société.
Bright Minds Biosciences (NASDAQ: DRUG) hat einen virtuellen F&E-Tag für den 20. Mai 2025 von 10:00 bis 11:30 Uhr ET angekündigt. Die Veranstaltung wird den Fokus des Unternehmens auf Absence-Anfälle und die laufende BREAKTHROUGH-Studie hervorheben – eine Phase-2-Studie zur Bewertung von BMB-101.
Der Webcast beinhaltet Präsentationen von Key Opinion Leaders (KOLs) in der Epilepsieforschung, die die ungedeckten Bedürfnisse von Epilepsiepatienten beleuchten. Die BREAKTHROUGH-Studie untersucht speziell die Sicherheit, Verträglichkeit und Wirksamkeit von BMB-101 bei erwachsenen Patienten mit klassischer Absence-Epilepsie und Entwicklungs- und epileptischer Enzephalopathie (DEE).
Der F&E-Tag ist über Webcast zugänglich, eine Wiederholung wird im Bereich 'Investoren' unter 'Veranstaltungen und Präsentationen' auf der Webseite des Unternehmens verfügbar sein.
- None.
- None.
VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that it will host a virtual R&D Day on Tuesday, May 20, 2025, from 10:00 am – 11:30 am ET.
The event will provide an overview of absence seizures and will focus on the unmet need in this group of epilepsy patients. The webcast will include presentations from renowned Key Opinion Leaders (KOLs) in epilepsy research, as well as an overview of the Company’s BREAKTHROUGH study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101 in adult patients with classic Absence Epilepsy and Developmental and Epileptic Encephalopathy (DEE). Attendees will have the opportunity to ask questions at the conclusion of the program.
Webcast Information
The Bright Minds Biosciences Virtual R&D Day will be webcast live and a replay will be available after the event by visiting the “Investors” section of the Company’s website and selecting “Events and Presentations.”
| Date & Time: | Tuesday, May 20, 2025, 10:00 am – 11:30 am ET |
| Webcast Access: | Click here |
About Bright Minds
Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.
Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.
Forward-Looking Statements
This news release contains “forward-looking information”. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include BMB’s hosting of the virtual R&D Day, and the contents of the program and webcast. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These factors include technical readiness to host an online webcast and continuation of anticipated content for the program. Additional risk factors can also be found in the Company’s public filings under the Company’s SEDAR+ profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances, management’s estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.
The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
Contact Information
Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com
Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
What is the purpose of Bright Minds Biosciences (DRUG) Phase 2 BREAKTHROUGH study?
When is Bright Minds Biosciences (DRUG) hosting its R&D Day in 2025?
What therapeutic areas does Bright Minds Biosciences (DRUG) focus on?
How can investors access Bright Minds Biosciences (DRUG) R&D Day presentation?
